Litcius/Paper detail

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas

Nitya Raj, Jennifer A. Chan, Stephanie J. Wang, Rahul Aggarwal, Susan Calabrese, April DeMore, Lawrence Fong, Jennifer A. Grabowsky, Thomas A. Hope, K. Kolli, Claire K. Mulvey, Pamela N. Münster, Kimberly Perez, Sippy Punn, Diane Reidy‐Lagunes, Sofia Von Fedak, Li Zhang, Emily K. Bergsland

2023British Journal of Cancer11 citationsDOIOpen Access PDF

Topics & Concepts

PembrolizumabMedicineInternal medicineChemotherapyOncologyResponse Evaluation Criteria in Solid TumorsAdverse effectGastroenterologyImmunotherapyCancerProgressive diseaseNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesThyroid Cancer Diagnosis and Treatment
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas | Litcius